Testosterone Cipionate
Castration-Resistant Prostate Carcinoma
Explore 215 assets in Castration-Resistant Prostate Carcinoma →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Roswell Park Cancer Institute
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06305598CT.gov Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT06039371CT.gov Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study | — | Recruiting | — | — | — |
NCT04704505CT.gov Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) | — | Recruiting | — | — | — |
NCT04363164CT.gov Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression | — | Recruiting | — | — | — |
NCT03554317CT.gov COMbination of Bipolar Androgen Therapy and Nivolumab | — | Completed | — | — | — |
NCT03516812CT.gov Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT02286921CT.gov Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Castration-Resistant Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Testosterone Cipionate (this asset) | Roswell Park Cancer Institute | P2 | BB · 64 |
| Darolutamide | Bayer | P4 | BBB |
| Enzalutamide | Prostate Cancer Clinical Trials Consortium | P4 | BBB |
| Prednisolone | Ding-Wei Ye | P4 | BBB |
| Cabozantinib | Rana McKay, MD | P3 | BB |
| Radium Ra-223 | University of California, San Francisco | P4 | BB |
| Mevrometostat | Prostate Cancer Clinical Trials Consortium | P3 | BB |
| Abiraterone | AstraZeneca | P4 | BB |
| Prednisone | Janssen Research & Development, LLC | P4 | BB |
+42 more in the Castration-Resistant Prostate Carcinoma cohort
Other indications for Testosterone Cipionate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hypogonadism, Male | — | P4 | B · 62 |
| Prostate Cancer | — | P4 | B · 61 |
| Substance-Related Disorder | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Testosterone Cipionate in Castration-Resistant Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/testosterone-cipionate-castration-resistant-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →